Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma

Effectiveness of combined therapy radiofrequency ablation/transarterial chemoembolization versus transarterial chemoembolization/radiofrequency ablation on management of hepatocellular carcinoma

“…Regarding the response to treatment according to RECIST criteria and CT finding after 1 and 7-month post-maneuvers in group I (TACE/RFA) versus group II (RFA/TACE); CR was achieved in 91% versus 100%, PR was achieved in 3% versus 0%, and PD was achieved in 6% versus 0%. The previous results approved by Othman et al [13] reported that CR in single HCC lesion (5–7 cm) after TACE/RFA, TACE, and RFA were 90, 70, and 60%, respectively. Peng et al [14] stated that CR in single HCC ≤7 cm or multiple HCC ≤3 each ≤3 cm was 97% after TACE/RFA and 93% after RFA alone.…”

“…As regards to LRR after 1 and 2 years were 15 and 50% after group I (TACE/RFA) versus 6% and 18% after group II (RFA/TACE), this results correlated with El Dorry et al [9] and Kim et al [16] revealed that LRR after 1 year was 16% after merging RFA then TACE and 9% after merging TACE then RFA, respectively. OS rates after first and second year were 85% and 65% after TACE/RFA versus 100% and 74% after RFA/TACE, respectively, which were in a harmony with; El Dorry et al [9] reported that 1 year OS rate was 88% and 80% in RFA/TACE and TACE alone group, respectively, Othman et al [13] resulted that OS after 1 year were 95% after TACE/RFA, 90% after RFA and 75% after TACE, and Peng et al [14] reported that OS after 1 and 3 years was 92.6% and 66.6% after TACE/RFA, and 85.3% and 59% after RFA, respectively. Othman et al [13] showed that disease-free survival rates after the first year follow-up were 90, 60, and 45% after TACE/RFA, TACE, and RFA, respectively; El Dorry et al [9] resulted that tumor-free survival rate after first year was 56% and 24% in RFA/TACE and TACE alone group, respectively; and Peng et al [14] who concluded that 1 and 3 years disease-free survival rate was 79.4 and 60.6% after TACE/RFA and 66.7 and 44.2% after RFA, respectively.…”

“…OS rates after first and second year were 85% and 65% after TACE/RFA versus 100% and 74% after RFA/TACE, respectively, which were in a harmony with; El Dorry et al [9] reported that 1 year OS rate was 88% and 80% in RFA/TACE and TACE alone group, respectively, Othman et al [13] resulted that OS after 1 year were 95% after TACE/RFA, 90% after RFA and 75% after TACE, and Peng et al [14] reported that OS after 1 and 3 years was 92.6% and 66.6% after TACE/RFA, and 85.3% and 59% after RFA, respectively. Othman et al [13] showed that disease-free survival rates after the first year follow-up were 90, 60, and 45% after TACE/RFA, TACE, and RFA, respectively; El Dorry et al [9] resulted that tumor-free survival rate after first year was 56% and 24% in RFA/TACE and TACE alone group, respectively; and Peng et al [14] who concluded that 1 and 3 years disease-free survival rate was 79.4 and 60.6% after TACE/RFA and 66.7 and 44.2% after RFA, respectively. All the previous results were in agreement with the present study which reported that 1-year and 2 years rate of tumor-free survival were 79 and 41% after TACE/RFA and 76 and 62% after RFA/TACE, respectively.…”

Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma

“…There were six studies [ 16 , 17 , 19 , 20 , 22 , 25 ] reported the recurrence-free survival rates. Heterogeneity was none among the studies ( P = 0.80, I 2 = 0%), so the fixed effect model was used to pool the outcomes.…”